Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
December 2020—Qiagen announced the European launch of the NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage Test, which aims to help health care professionals identify and differentiate between patients with common seasonal respiratory infections and COVID-19. The multiplex PCR test detects and differentiates influenzas A and B, respiratory syncytial virus, and SARS-CoV-2 infections within 80 minutes.
December 2020—Eppendorf released its Move It Adjustable Spacing Pipettes. Move It was designed for the synchronous pipetting of a series of samples between different vessel formats, such as between tubes and plates, without tubing connections between cone and piston-cylinder system. The format of microplates can be adjusted directly with the format limiters. For other sample tubes or tubes in holders, the cone spacing is selected by using the rotary knob.
December 2020—OralDNA Labs announced that the FDA issued an amended emergency use authorization for the OraRisk COVID-19 RT-PCR test, allowing testing from a saline oral rinse collection. Samples are viable for up to 72 hours and do not require cold pack transportation.
December 2020—Fabric Genomics launched Fabric GEM, a novel algorithm that identifies the likely genetic cause of rare diseases using next-generation sequencing.
December 2020—BD announced its rapid, point-of-care, SARS-CoV-2 antigen test for use on the BD Veritor Plus system has been CE marked to the IVD directive. The test delivers results in 15 minutes and has been authorized by the FDA under an EUA for use by authorized laboratories.
December 2020—Agena Bioscience’s MassArray SARS-CoV-2 Panel for qualitative detection of the SARS-CoV-2 coronavirus has been granted emergency use authorization from the FDA.
December 2020—The FDA approved the Guardant360 CDx assay (Guardant Health), a liquid biopsy companion diagnostic that also uses next-generation sequencing technology to identify patients with specific types of mutations of the epidermal growth factor receptor gene in a deadly form of metastatic non-small cell lung cancer. This is the first approval to combine NGS and liquid biopsy in one diagnostic test in order to guide treatment decisions.
November 2020—Magnolia Medical Technologies launched Mission to Zero to bring greater awareness to patient safety and antibiotic-associated risks caused by false-positive diagnostic test results for sepsis. Magnolia is launching the initiative by partnering with emergency departments, critical care units, clinical laboratories, and infection prevention teams within acute care hospitals. Each team member makes an individual pledge to participate, the company says, which allows all departments to work in tandem to ensure the best possible patient outcomes and experience are achieved.
November 2020—Cepheid received emergency use authorization from the FDA for its Xpert Xpress SARS-CoV-2/Flu/RSV, a rapid molecular diagnostic test for qualitative detection of the viruses that cause COVID-19, flu A, flu B, and RSV infections from a single patient sample.
November 2020—Siemens Healthineers received FDA emergency use authorization for the SARS-CoV-2 IgG antibody test. It is the first antibody test authorized with a semiquantitative detection claim.
